Literature DB >> 8853167

Bone remodelling in monoclonal gammopathies of uncertain significance, symptomatic and nonsymptomatic myeloma.

M Laroche1, M Attal, C Dromer.   

Abstract

In order to characterize the abnormalities of bone remodelling in the various stages of plasma cell disorders, we studied 60 patients (29 monoclonal gammopathies of uncertain significance (MGUS), 13 stage I myeloma, 18 stage III myeloma). We carried out histomorphometric study of bone biopsies in 34 patients and measurement of osteocalcin and the calciuria/creatinine ratio. Bone remodelling was approximately normal (BV/TV:21.2 +/- 7, ES:4.1 +/- 2, OS:16.5 +/- 10) in MGUS. Stage I myeloma was characterised by parallel increases in resorption surfaces and osteoid surfaces (BV/TV:18 +/- 5, ES/BS:7.4 +/- 3.5, OS/BS:24.8 +/- 11.5), of the ca/cr ratio and osteocalcin. In stage III myeloma, resorption surfaces and the ca/cr ratio showed an even greater increase while osteoid surfaces, osteocalcin and trabecular bone volume decreased (BV/TV 13.6 +/- 6, ES/BS:12.1 +/- 6, OS/BS:13.6 +/- 8.3). Osteocalcin and osteoid surfaces were correlated (r = 0.5). There was a positive correlation between osteocalcin and the number of plasmocytes in stage 1 myeloma (r = 0.64) and a negative correlation in stage III myeloma (r = 0.9). Bone remodeling was normal in MGUS; bone remodelling grew with a parallel increase of formation and resorption in stage I; bone resorption increased while bone formation decreased in stage III myeloma.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8853167     DOI: 10.1007/bf02230356

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  23 in total

1.  Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee.

Authors:  A M Parfitt; M K Drezner; F H Glorieux; J A Kanis; H Malluche; P J Meunier; S M Ott; R R Recker
Journal:  J Bone Miner Res       Date:  1987-12       Impact factor: 6.741

2.  Ineffectiveness of fluoride therapy in multiple myeloma.

Authors:  J B Harley; A Schilling; O Glidewell
Journal:  N Engl J Med       Date:  1972-06-15       Impact factor: 91.245

3.  Multiple-myeloma bone disease. The comparative effect of sodium fluoride and calcium carbonate or placebo.

Authors:  R A Kyle; J Jowsey; P J Kelly; D R Taves
Journal:  N Engl J Med       Date:  1975-12-25       Impact factor: 91.245

4.  Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group.

Authors:  R Lahtinen; M Laakso; I Palva; P Virkkunen; I Elomaa
Journal:  Lancet       Date:  1992-10-31       Impact factor: 79.321

5.  Biologic, histologic and densitometric effects of oral risedronate on bone in patients with multiple myeloma.

Authors:  C Roux; P Ravaud; M Cohen-Solal; M C de Vernejoul; S Guillemant; B Cherruau; P Delmas; M Dougados; B Amor
Journal:  Bone       Date:  1994 Jan-Feb       Impact factor: 4.398

6.  [Contribution of bone biopsy with histomorphometry in the evaluation of monoclonal gammopathy].

Authors:  C Alexandre; R Bataille; D Chappard; P Dessauw; J Sany; G Riffat
Journal:  Rev Rhum Mal Osteoartic       Date:  1987-11

7.  Serum bone gamma carboxyglutamic acid-containing protein in primary hyperparathyroidism and in malignant hypercalcemia. Comparison with bone histomorphometry.

Authors:  P D Delmas; B Demiaux; L Malaval; M C Chapuy; C Edouard; P J Meunier
Journal:  J Clin Invest       Date:  1986-03       Impact factor: 14.808

8.  Risk of disease progression in asymptomatic multiple myeloma.

Authors:  M A Dimopoulos; A Moulopoulos; T Smith; K B Delasalle; R Alexanian
Journal:  Am J Med       Date:  1993-01       Impact factor: 4.965

9.  Serum osteocalcin in the management of myeloma.

Authors:  A T Williams; M J Shearer; J Oyeyi; R G Aitchison; A C Newland; S A Schey
Journal:  Eur J Cancer       Date:  1992       Impact factor: 9.162

10.  Quantitative histology of myeloma-induced bone changes.

Authors:  A Valentin-Opran; S A Charhon; P J Meunier; C M Edouard; M E Arlot
Journal:  Br J Haematol       Date:  1982-12       Impact factor: 6.998

View more
  7 in total

Review 1.  unveiling skeletal fragility in patients diagnosed with MGUS: no longer a condition of undetermined significance?

Authors:  Matthew T Drake
Journal:  J Bone Miner Res       Date:  2014-12       Impact factor: 6.741

2.  Bone disease in monoclonal gammopathy of undetermined significance: results from a screened population-based study.

Authors:  Sigrun Thorsteinsdottir; Sigrun H Lund; Ebba K Lindqvist; Marianna Thordardottir; Gunnar Sigurdsson; Rene Costello; Debra Burton; Hlif Steingrimsdottir; Vilmundur Gudnason; Gudny Eiriksdottir; Kristin Siggeirsdottir; Tamara B Harris; Ola Landgren; Sigurdur Y Kristinsson
Journal:  Blood Adv       Date:  2017-12-21

Review 3.  Bone disease in multiple myeloma and precursor disease: novel diagnostic approaches and implications on clinical management.

Authors:  Sigurdur Y Kristinsson; Alex R Minter; Neha Korde; Esther Tan; Ola Landgren
Journal:  Expert Rev Mol Diagn       Date:  2011-07       Impact factor: 5.225

4.  Monoclonal gammopathy of undetermined significance and risk of skeletal fractures: a population-based study.

Authors:  Sigurdur Y Kristinsson; Min Tang; Ruth M Pfeiffer; Magnus Björkholm; Cecilie Blimark; Ulf-Henrik Mellqvist; Anders Wahlin; Ingemar Turesson; Ola Landgren
Journal:  Blood       Date:  2010-07-07       Impact factor: 22.113

5.  Bone microstructural changes revealed by high-resolution peripheral quantitative computed tomography imaging and elevated DKK1 and MIP-1α levels in patients with MGUS.

Authors:  Alvin C Ng; Sundeep Khosla; Natthinee Charatcharoenwitthaya; Shaji K Kumar; Sara J Achenbach; Margaret F Holets; Louise K McCready; L Joseph Melton; Robert A Kyle; S Vincent Rajkumar; Matthew T Drake
Journal:  Blood       Date:  2011-10-31       Impact factor: 22.113

Review 6.  Hematological Diseases and Osteoporosis.

Authors:  Agostino Gaudio; Anastasia Xourafa; Rosario Rapisarda; Luca Zanoli; Salvatore Santo Signorelli; Pietro Castellino
Journal:  Int J Mol Sci       Date:  2020-05-16       Impact factor: 5.923

7.  Multiple myeloma: changes in serum C-terminal telopeptide of collagen type I and bone-specific alkaline phosphatase can be used in daily practice to detect imminent osteolysis.

Authors:  Thomas Lund; Niels Abildgaard; Thomas L Andersen; Jean-Marie Delaisse; Torben Plesner
Journal:  Eur J Haematol       Date:  2010-01-13       Impact factor: 2.997

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.